Malignant Thoracic Neoplasm

In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7）and disease control rate was … (full text at CIViC)

Open in CIViC

In a retrospective study of stage IV NSCLC patients treated with first-line platinum doublet chemotherapy (n = 103; 51 KEAP1/NFE2L2/CUL3-mutant, 52 WT), mutations in NFE2L2, KEAP1, or CUL3 were associ… (full text at CIViC)

PMID 31548347 · Jeong et al., 2020 · Open in CIViC

NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC)

PMID 27693535 · Klempner et al., 2017 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK T1151M co-mutation, demonstrated resistance to crizotinib treatment (IC50: 346.65… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines. siRNA knockdown of NQO1 (in two cell lines) i… (full text at CIViC)

PMID 21964527 · Takakuwa et al., 2011 · Open in CIViC

The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for … (full text at CIViC)

PMID 21964527 · Takakuwa et al., 2011 · Open in CIViC

Mice that carried the Q61H variant had Malignant Pleural Mesothelioma and Lewis Lung Carincoma. The malignant cells where taken and each cell line was shown to readily promote lung colonization compar… (full text at CIViC)

PMID 28341702 · Giannou et al., 2017 · Open in CIViC

In an in vitro study, a PC-9 cell line expressing NRAS Q61K mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing NRAS wild-type. Sensitivity was determi… (full text at CIViC)

PMID 22773810 · Ohashi et al., 2012 · Open in CIViC

NRAS mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations ar… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC)

PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC

In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decrea… (full text at CIViC)

PMID 23390248 · Hegde et al., 2013 · Open in CIViC

A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.

PMID 30624546 · Hong et al., 2019 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

25 tumors from individuals with lung adca who have <= 10 pack-year smoking history underwent whole exome sequencing and RNA-seq. 5 tumors did not identify an established oncogenic driver. In one (tumo… (full text at CIViC)

PMID 35247929 · Hunihan et al., 2022 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.

PMID 26745678 · Li et al., 2016 · Open in CIViC

PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.

PMID 25928036 · Xu et al., 2015 · Open in CIViC

Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H… (full text at CIViC)

PMID 19755855 · Ramos et al., 2009 · Open in CIViC

In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression … (full text at CIViC)

PMID 19366796 · McDermott et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM). The presence of p1… (full text at CIViC)

PMID 16906227 · Engelman et al., 2006 · Open in CIViC

48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed… (full text at CIViC)

PMID 27304188 · Belchis et al., 2016 · Open in CIViC

Lung adenocarcinoma cell lines with MET exon 14 skipping mutation and PIK3CA mutation (H596) were tested with GDC0941 (pictilisib) alone and with crizotinib. Analysis shows a statistically significant… (full text at CIViC)

PMID 26215952 · Liu et al., 2016 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha … (full text at CIViC)

PMID 19029981 · Engelman et al., 2008 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patien… (full text at CIViC)

PMID 21258250 · Ludovini et al., 2011 · Open in CIViC

In a phase II trial,patients with squamous NSCLC harboring PIK3CA mutations were treated with PI3K inhibitor taselisib. The study was closed for futility at interim analysis with one responder (Respon… (full text at CIViC)

PMID 31158500 · Langer et al., 2019 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC